WELWYN GARDEN CITY, England and BOSTON, April 2, 2013 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery company, notes that Dan Grau (Heptares' President) will attend the Boston Biotech BD Conference taking place at the Four Seasons Hotel, Boston, MA, USA (2-3 April), at which he will participate in a panel discussion entitled Listening to Patients While Setting Company Goals: More Important than Ever? (2:00-2:30pm, 3 April).
In addition, Mr Grau will attend BioCentury's 20th Annual Future Leaders in the Biotech Industry conference taking place at the Millennium Broadway Hotel, New York City, NY, USA on Friday, 5 April, at which he will present a company overview (8:30-8:55am, Presentation Room 302/303).
For a full list of events at which Heptares will be present, please visit http://www.heptares.com
About Heptares Therapeutics Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, Cubist, Takeda, MorphoSys, AstraZeneca and MedImmune, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit: http://www.heptares.com
SOURCE Heptares Therapeutics